August 2026 did not bring a novel FDA-approved acne drug; the FDA's 2026 novel-drug list, current through August 27, contains no acne treatment. The meaningful developments were wider nonprescription access, delayed isotretinoin rules, and a Phase 3 trial cleared to proceed. For readers, the immediate changes concern how treatments are obtained and managed—not a newly approved acne medicine. The main research questions involve denifanstat and whether early evidence on fish oil with low-dose isotretinoin holds up in larger, longer studies.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- A prescription acne combination moved over the counter
- The new iPLEDGE rules are not active yet
- Denifanstat reached Phase 3 clearance, not approval
- Fish oil and low-dose isotretinoin showed an early signal
- Keep the benzoyl-peroxide recall findings in perspective
A prescription acne combination moved over the counter
On May 22, the FDA approved Differin Epiduo acne Gel for prescription-to-nonprescription sale. The product combines adapalene 0.1% and benzoyl peroxide 2.5% and is intended for adults and children aged 12 or older, according to the FDA's switch list. This is an access change, not approval of a novel drug.
It allows eligible consumers to obtain this established combination without first getting a prescription. Check the active ingredients and age indication rather than relying only on the brand name. Anyone already using a retinoid or benzoyl-peroxide product should also compare ingredients before adding the combination, preferably with a pharmacist or clinician.
The new iPLEDGE rules are not active yet
The FDA delayed its modified iPLEDGE program from August 8 to November 15, 2026, according to its June iPLEDGE notice. iPLEDGE is the safety program that controls access to isotretinoin because of pregnancy risks. Once implemented, the modifications would let prescribers permit at-home pregnancy tests during and after treatment.
They would also remove the repeat-test waiting period after a missed seven-day prescription window and end monthly counseling documentation for patients who cannot get pregnant. Pretreatment pregnancy testing would still occur in a medical setting. Until November 15, patients, prescribers, and pharmacies should follow the currently operating requirements. Do not assume a home test is accepted, a missed-window waiting period has disappeared, or monthly documentation has ended without confirming the applicable rule.
Denifanstat reached Phase 3 clearance, not approval
On August 13, Sagimet Biosciences reported that the FDA cleared its investigational new drug application for denifanstat and issued a "Study May Proceed" letter, as described in the company's announcement. Denifanstat is an oral fatty-acid-synthase inhibitor being studied for moderate-to-severe acne. The clearance permits a U.S. trial; it does not authorize the drug for sale.
The planned Phase 3 study would enroll about 800 people aged 12 or older, including approximately 450 adolescents. It includes 12 weeks of placebo-controlled efficacy testing followed by a 40-week open-label safety extension. A July 2026 Phase 2 trial found greater reductions in total lesions than placebo at every tested dose after 12 weeks. However, differences in a separate global-assessment success measure were not statistically significant. Enrollment, longer-term safety findings, and agreement across Phase 3 endpoints are therefore the next meaningful watch points.
Fish oil and low-dose isotretinoin showed an early signal
An August 2026 randomized trial studied 80 adults aged 18 to 25 for three months. Participants receiving 1 gram of fish oil daily with 10 milligrams of isotretinoin daily had total-acne reductions that were noninferior to isotretinoin alone, meaning the combination stayed within the study's preset comparison margin. The combination group also had smaller decreases in skin hydration and smaller triglyceride increases.
These findings suggest a possible supportive role for fish oil, but they do not establish benefits beyond three months or in people outside the study's narrow age range. The trial does not justify independently reducing an isotretinoin dose or adding a supplement. Patients should discuss any regimen change with the clinician managing their isotretinoin treatment.
Keep the benzoyl-peroxide recall findings in perspective
Benzoyl-peroxide safety remains relevant because the newly switched gel contains that ingredient, but the major FDA testing update came in March 2025—not August 2026. The FDA tested 95 acne products, found six with elevated benzene, and reported that more than 90% had undetectable or extremely low levels. The resulting voluntary recalls occurred at the retail level.
The findings did not amount to a recall of every benzoyl-peroxide acne treatment. Consumers should compare their exact product with the FDA's listed products and discard expired stock. Do not assume that the nonprescription switch itself identifies Differin Epiduo Acne Gel as one of the recalled products; the cited evidence makes no such connection.